Ionis fills pivotal Angelman syndrome cohort, but can obudanersen confirm its early promise?
Discover why Ionis' REVEAL enrollment turns obudanersen into a decisive Phase 3 test for Angelman syndrome treatment.
Pharma & Biotech
Pharma & Biotech
Is BRC Therapeutics opening a new regulatory lane for cannabinoid-based CRPS therapies?
CRPS has no approved U.S. therapy. BRC-002 now has an FDA path, but proof of safety, efficacy, and dosing discipline still lies ahead.
Pharma & Biotech
What Matricelf’s Parkinson’s spinout reveals about the future of cell based neurodegeneration therapies
Matricelf plans a subsidiary to commercialize its Parkinson’s therapy platform. Discover what this move signals for regenerative medicine and neurology innovation.
Pharma & Biotech
Scribe Therapeutics deepens in vivo CRISPR validation with second Eli Lilly collaboration milestone
Scribe Therapeutics hits a second in vivo CRISPR milestone with Eli Lilly. Explore what this changes for gene editing platforms and future therapies.